Section 503B governs FDA-registered outsourcing facilities — the large-scale compounders that produce sterile injectables in bulk for hospitals, clinics, and telehealth platforms. Under 503B, a facility may only compound from a bulk drug substance if that substance appears on the 503B bulks list or the finished drug is on the FDA shortage list at the time of compounding.
The 503B story in 2026 has been written around the GLP-1 supply chain. The FDA declared the tirzepatide shortage resolved in October 2024 and semaglutide in February 2025, then on April 30, 2026 proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the procedural step that would close the legal pathway for outsourcing facilities to keep producing copies. The Partnership for Safe Medicines applauded the move; Orrick's May client memo translated the implications for telehealth platforms and weight-loss clinics. Comments are open through June 29, 2026.
Stories here cover the proposal, comment-period stakeholders, and the Outsourcing Facilities Association lawsuit. See #503a, #compounding, and #fda for adjacent threads.
Hims & Hers reports Q1 2026 after market close May 11, with consensus revenue at $616-619M and EPS at roughly 3-4 cents — a 90% YoY decline. The investor question is whether the legitimate Wegovy/Ozempic distribution channel from the Novo Nordisk partnership (signed April 2026) can offset the wind-down of the compounded semaglutide business. Novo's branded products were not on the platform until March 26, with Q1 books closing March 31 — meaningful Wegovy revenue contribution likely lands in Q2. Subscriber count above 2.5M and ~82% three-month retention remain the standing benchmarks. The April 30 FDA proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list raises the medium-term bar for any compounding-driven model.
The Partnership for Safe Medicines issued a May statement strongly supporting the FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, citing 'sound science, sound law, and a clear-eyed commitment to patient safety.' The Partnership cited more than 455 adverse-event reports linked to compounded semaglutide and more than 320 tied to compounded tirzepatide — many involving dosing errors from multidose vials, some leading to hospitalization — as the safety basis. The group plans to submit a full comment to the Federal Register docket before the June 29 deadline and is encouraging other patient-safety groups to do the same.
Orrick published a May 2026 client memo walking through the FDA's April 30 proposal to formally exclude semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B outsourcing-facility bulk drug substances list. The memo flags that the FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, removing the two legal pathways that previously enabled large-scale compounding. Orrick advises weight-loss clinics, medical spas, and telehealth platforms still relying on compounded GLP-1 products to consult counsel ahead of the June 29 comment deadline.
The FDA announced a proposal on April 30 to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, finding no clinical need for large-scale compounding now that branded supply has stabilized. Commissioner Marty Makary said outsourcing facilities cannot lawfully compound from bulk substances when FDA-approved drugs are available unless a clear clinical need exists. Public comments are open through June 29, 2026. The proposal targets 503B outsourcing facilities only and does not directly affect 503A patient-specific compounding, but it forecloses the largest legal pathway for branded-active GLP-1 compounding.
Pharmacy law firm Holt Law published a detailed regulatory analysis of how the FDA's April 22 Category 2 removals interact with state pharmacy boards, 503A vs 503B compounding pathways, and physician prescribing requirements. The analysis emphasizes that Category 2 removal is not the same as 503A bulk-list inclusion, and that compounding pharmacies face material legal risk if they begin producing reclassified peptides before the July 23-24 PCAC meeting. The piece is a working reference for pharmacy operations preparing for the post-PCAC environment.